Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($)		3 Months Ended	9 Months Ended
	Sep. 12, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 12, 2024	Mar. 12, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 125,000,000
Potential revenue interest second payment to be received	$ 75,000,000
Purchase agreement, second payment date	Sep. 12, 2025
Potential revenue interest third payment to be received	$ 50,000,000
Purchase agreement, third payment date	Sep. 12, 2025
Applicable payment percentage of quarterly revenue base for first payment	5.00%
Applicable payment percentage of quarterly revenue base for first and second payment	8.00%
Applicable payment percentage of quarterly revenue base for first, second and third payment	10.00%
Revenue interest payment term	45 days
Cumulative purchaser payments receivable date	Sep. 12, 2028
Percentage of revenue interest payments	100.00%
Percentage of cumulative purchaser payments	165.00%
Cumulative purchaser payments repayment date	Sep. 12, 2032
Increase in return cap percentage of cumulative purchaser payments	175.00%
Amortization of purchase agreement obligation			$ 0
Effective interest rate		11.50%	11.50%
Debt issuance costs		$ 600,000	$ 600,000
Noncash interest expense recognized		$ 700,000	$ 700,000
Forecast | Put/Call Options
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of cumulative purchaser payments				125.00%	120.00%
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue interest payment to be received	$ 125,000,000